CDME Module 9: Scheduled Drug Use and Alcoholism (2025)-Expert Panel Commentary and Recommendations: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety. Presented to the FMCSA, December 9, 2006.

Expert Panel Commentary and Recommendations: Licit Schedule II Drug Use and Commercial Motor Vehicle Driver Safety. Presented to the FMCSA, December 9, 2006.

Back to course

Pdf Summary

The document presented is an expert panel commentary and recommendations concerning the use of licit Schedule II drugs by Commercial Motor Vehicle (CMV) drivers and the associated safety implications. It was prepared for the U.S. Department of Transportation's Federal Motor Carrier Safety Administration (FMCSA). The key points revolve around evaluating whether prescribed Schedule II drugs (opioids, stimulants, and depressants) impact driver ability and the risk of vehicle crashes.<br /><br />The Safe, Accountable, Flexible, Efficient Transportation Equity Act mandates that the Secretary of Transportation, with guidance from medical review boards, establish and revise medical standards ensuring CMV operators are physically capable of safely conducting their duties. The panel, composed of selected experts, was tasked with reviewing scientific literature to inform FMCSA's guidelines on Schedule II drug use.<br /><br />Key inquiries the panel explored included:<br />1. The risk of motor vehicle crashes correlated with prescribed Schedule II drug use.<br />2. Whether these drugs negatively impact indirect driving measures like cognitive ability and psychomotor functions.<br />3. Correlations between serum drug levels and crash risk.<br />4. Potential interactions among prescribed Schedule II drugs and other medications.<br /><br />The panel found a considerable lack of high-quality data specifically correlating licit Schedule II drug use with increased crash risk and impact on driving ability. However, where studies were available, some indicated potential negative effects on psychomotor and cognitive functions, particularly with first-time opioid use or chronic opioid treatment. The panel advised eliminating exceptions allowing CMV operation under these medications unless appropriately documented by medical professionals, emphasizing the importance of public safety over individual interests.<br /><br />The panel recommended further research into a broader list of controlled substances beyond Schedule II, considering potential interactions and substances like benzodiazepines that may also impact driving safety. They urged improvements in guidance for medical examiners, encouraging the development of standardized reporting and follow-up procedures for drivers using these substances. They also highlighted the need for expanded safety education among carriers and drivers about medication-associated risks.

Keywords

Schedule II drugs

Commercial Motor Vehicle

safety implications

opioids

stimulants

depressants

FMCSA guidelines

cognitive ability

psychomotor functions

drug interactions